HRP20230989T1 - Novi sastavi željeza i metode njihove izrade i upotrebe - Google Patents

Novi sastavi željeza i metode njihove izrade i upotrebe Download PDF

Info

Publication number
HRP20230989T1
HRP20230989T1 HRP20230989TT HRP20230989T HRP20230989T1 HR P20230989 T1 HRP20230989 T1 HR P20230989T1 HR P20230989T T HRP20230989T T HR P20230989TT HR P20230989 T HRP20230989 T HR P20230989T HR P20230989 T1 HRP20230989 T1 HR P20230989T1
Authority
HR
Croatia
Prior art keywords
composition
iron solution
use according
aqueous
aqueous iron
Prior art date
Application number
HRP20230989TT
Other languages
English (en)
Croatian (hr)
Inventor
Donald Jeffrey Keyser
Alvaro F. Guillem
Richard A. ZAGER
Original Assignee
Renibus Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renibus Therapeutics, Inc. filed Critical Renibus Therapeutics, Inc.
Publication of HRP20230989T1 publication Critical patent/HRP20230989T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/26Iron; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HRP20230989TT 2019-02-28 2020-02-28 Novi sastavi željeza i metode njihove izrade i upotrebe HRP20230989T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962812028P 2019-02-28 2019-02-28
PCT/US2020/020517 WO2020176894A1 (en) 2019-02-28 2020-02-28 Novel iron compositions and methods of making and using the same
EP20717359.2A EP3930686B1 (en) 2019-02-28 2020-02-28 Novel iron compositions and methods of making and using the same

Publications (1)

Publication Number Publication Date
HRP20230989T1 true HRP20230989T1 (hr) 2023-12-08

Family

ID=70190086

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20230989TT HRP20230989T1 (hr) 2019-02-28 2020-02-28 Novi sastavi željeza i metode njihove izrade i upotrebe

Country Status (20)

Country Link
US (4) US11292813B2 (https=)
EP (2) EP3930686B1 (https=)
JP (3) JP7320611B2 (https=)
KR (1) KR20210133243A (https=)
CN (2) CN119488480A (https=)
AU (2) AU2020229381A1 (https=)
CA (1) CA3131596A1 (https=)
DK (1) DK3930686T3 (https=)
ES (1) ES2955019T3 (https=)
FI (1) FI3930686T3 (https=)
HR (1) HRP20230989T1 (https=)
HU (1) HUE063182T2 (https=)
LT (1) LT3930686T (https=)
PL (1) PL3930686T3 (https=)
PT (1) PT3930686T (https=)
RS (1) RS64652B1 (https=)
SG (1) SG11202109323UA (https=)
SI (1) SI3930686T1 (https=)
SM (1) SMT202300276T1 (https=)
WO (1) WO2020176894A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022056378A1 (en) * 2020-09-11 2022-03-17 Renibus Therapeutics, Inc. Method for treating cancer with kidney protection
WO2024069644A1 (en) * 2022-09-30 2024-04-04 West Bengal Chemical Industries Limited A pharmaceutically acceptable ferric carboxymaltose and preparation thereof
CN115969714B (zh) * 2022-11-03 2025-03-11 华熙生物科技股份有限公司 具有光谱选择性的防晒组合物及其应用
WO2025047574A1 (ja) 2023-08-29 2025-03-06 株式会社ダイセル 硬化性エポキシ組成物

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE862482C (de) * 1950-05-14 1953-01-12 Merck Chem Fab E Verfahren zur Darstellung haltbarer, injizierbarer Loesungen von Salzen des dreiwertigen Eisens
US5624668A (en) 1995-09-29 1997-04-29 Luitpold Pharmaceuticals, Inc. Iron dextran formulations
DE19547356A1 (de) * 1995-12-19 1997-06-26 Vifor Int Ag Adsorbens für Phosphat aus wäßrigem Medium, dessen Herstellung und Verwendung
US20030232738A1 (en) * 1998-04-20 2003-12-18 National Jewish Medical And Research Center Method and composition for increasing CD4+ T lymphocyte immune responsiveness
CA2365787C (en) * 2000-12-20 2006-02-14 Dialysis Solutions Inc. Sterile low bicarbonate dialysis concentrate solutions
WO2004019032A1 (en) * 2002-08-26 2004-03-04 Luitpold Pharmaceuticals, Inc. Bioequivalence test for iron-containing formulations
WO2005094202A2 (en) * 2004-03-16 2005-10-13 Navinta, Llc Iron sucrose complexes and method of manufacture thereof
EP1819720B1 (en) 2004-12-06 2013-05-15 Emcure Pharmaceuticals Limited A cost-effective process for preparation of manufacture of iron sucrose
ITMO20050056A1 (it) 2005-03-15 2006-09-16 Biofer Spa Processo per la preparazione di complessi del ferro trivalente con zuccheri mono-, di- e polisaccaridi.
CN100528237C (zh) 2005-04-26 2009-08-19 重庆医药工业研究院有限责任公司 多核的氢氧化铁-糖复合物的制备方法
EP1757299A1 (de) * 2005-08-25 2007-02-28 Vifor (International) Ag Eisen(III)-Komplexverbindungen zur Behandlung von Eisenmangel-Zuständen bei Patienten mit chronisch-entzündlicher Darmerkrankung
US7960371B2 (en) 2006-10-04 2011-06-14 Infacare Pharmaceutical Corporation High-purity large-scale preparation of stannsoporfin
EP1947120A1 (de) 2007-01-19 2008-07-23 Vifor (International) Ag Eisen-Kohlenhydrat-Komplex-Verbindungen
IN269965B (https=) 2007-06-25 2015-11-27 Claris Lifescienses Ltd
TWI592159B (zh) 2007-11-16 2017-07-21 威佛(國際)股份有限公司 藥學組成物
AR076070A1 (es) * 2009-03-02 2011-05-18 Vifor Int Ag Absorbente de fosfato para el tratamiento de la hiperfosfatemia
CN102451185A (zh) * 2010-10-19 2012-05-16 长春纳米生技公司 金属离子纳米簇组合物
EP2548562A1 (de) 2011-07-18 2013-01-23 SeBo GmbH Kombinationstherapie mit Eisen-basierenden Phosphatadsorbern
EP2647389A1 (en) * 2012-04-04 2013-10-09 Charité - Universitätsmedizin Berlin Magnetic nanoparticle dispersion, its preparation and diagnostic and therapeutic use
CN103340827B (zh) 2013-07-16 2014-12-10 成都天台山制药有限公司 蔗糖铁注射液及其制法
CN104558064A (zh) 2013-10-29 2015-04-29 北京京卫信康医药科技发展有限公司 蔗糖铁的制备方法
IN2013CH05383A (https=) 2013-11-21 2015-08-28 Reddy’S Lab Ltd Dr
CN104098616B (zh) 2014-05-27 2016-04-20 广西壮族自治区化工研究院 一种蔗糖铁的制备方法
SI3200582T1 (sl) * 2014-09-29 2024-04-30 Fred Hutchinson Cancer Center Sestave, kompleti in metode za indukcijo pridobljene citorezistence z uporabo induktorjev stresnih proteinov
WO2017165692A1 (en) * 2016-03-23 2017-09-28 Fred Hutchinson Cancer Research Center Compounds linked with a saccharide metal complex and uses thereof
US20190358242A1 (en) * 2017-02-08 2019-11-28 Fred Hutchinson Cancer Research Center Compositions, kits, and methods to induce acquired cytoresistance using stress protein inducers
HUE070809T2 (hu) 2017-09-11 2025-07-28 Pharmacosmos Holding As Vaskomplex vegyületek gyógyászati alkalmazásra
CN109912675B (zh) 2017-12-13 2020-09-15 北京市林业果树科学研究院 一种蔗糖亚铁及其制备方法
CN110063965A (zh) 2019-06-04 2019-07-30 吉林省富生医疗器械有限公司 一种血液透析浓缩物
CN112315902B (zh) 2019-08-05 2022-05-13 南京恒生制药有限公司 一种低易变铁含量蔗糖铁注射液制备方法
CN112168844A (zh) 2020-09-29 2021-01-05 神奈纳米医药技术(珠海)有限公司 一种氢氧化铁碳水化合物复合物的制备方法
MY210100A (en) 2020-09-29 2025-08-27 Lg Bionano Llc Methods of preparing iron complexes
CN112156109A (zh) 2020-09-29 2021-01-01 神奈纳米医药技术(珠海)有限公司 氢氧化铁-糖络合物的制备方法及其应用
CN115531414A (zh) 2021-06-30 2022-12-30 南京恒生制药有限公司 一种新型蔗糖铁复合物及其制备方法
CN118103047A (zh) 2021-08-27 2024-05-28 美国瑞根特有限公司 铁组合物及其制备和使用方法

Also Published As

Publication number Publication date
ES2955019T3 (es) 2023-11-28
US11292813B2 (en) 2022-04-05
US11840552B2 (en) 2023-12-12
KR20210133243A (ko) 2021-11-05
US11834471B2 (en) 2023-12-05
SMT202300276T1 (it) 2023-11-13
SG11202109323UA (en) 2021-09-29
CN113825496B (zh) 2024-09-27
FI3930686T3 (fi) 2023-09-01
WO2020176894A1 (en) 2020-09-03
CA3131596A1 (en) 2020-09-03
HUE063182T2 (hu) 2024-01-28
PL3930686T3 (pl) 2023-11-27
JP2022522009A (ja) 2022-04-13
JP7646750B2 (ja) 2025-03-17
CN113825496A (zh) 2021-12-21
AU2020229381A1 (en) 2021-09-16
EP3930686A1 (en) 2022-01-05
JP2023139154A (ja) 2023-10-03
US20230070012A1 (en) 2023-03-09
CN119488480A (zh) 2025-02-21
LT3930686T (lt) 2023-10-10
DK3930686T3 (da) 2023-09-11
RS64652B1 (sr) 2023-10-31
EP4234020A3 (en) 2023-10-04
PT3930686T (pt) 2023-09-04
JP7320611B2 (ja) 2023-08-03
US20220242901A1 (en) 2022-08-04
US20200277325A1 (en) 2020-09-03
US20240002427A1 (en) 2024-01-04
JP2025084949A (ja) 2025-06-03
AU2025230678A1 (en) 2025-10-02
EP4234020A2 (en) 2023-08-30
SI3930686T1 (sl) 2023-11-30
EP3930686B1 (en) 2023-05-31

Similar Documents

Publication Publication Date Title
HRP20230989T1 (hr) Novi sastavi željeza i metode njihove izrade i upotrebe
JP2006501133A5 (https=)
HRP20241461T1 (hr) Aprocitentan za uporabu u liječenju hipertenzije i povezanih bolesti u kombinaciji s valsartanom
ME02520B (me) Farmaceutske kompozicije
RU2007111713A (ru) Фармацевтическая композиция для перорального введения в форме частиц с рассчитанным временем высвобождения и быстро распадающиеся таблетки, содержащие указанную композицию
RU2010141542A (ru) Низковязкие высокофлокулированные суспензии триамцинолона ацетонида для интравитреальных инъекций
RU2013103534A (ru) Лечение легочных инфекций с помощью введения тобрамицина путем аэролизации
CO6260019A2 (es) Metodos para el tratamiento de desordenes gastrointestinales independientes de la ingesta de alimento
MD20070267A (en) Gastroresistant pharmaceutical formulation containing rifaximin
HRP20191477T1 (hr) Farmaceutski sastav s-ketamin hidroklorida
HRP20240086T1 (hr) Režimi za doziranje povezani s injektibilnim formulacijama paliperidona s produljenim oslobađanjem
SE8602722D0 (sv) Hallbara administreringsformer
HRP20241457T1 (hr) Sredstva za degradaciju porodice cinkovih prstiju ikaros i njihova uporaba
HRP20110713T1 (hr) Postupci liječenja kroničnog virusnog hepatitisa c uz upotrebu ro 113-0830
JP2025084949A5 (https=)
HRP20240074T1 (hr) Režimi za doziranje povezani s injektibilnim formulacijama paliperidona s produljenim oslobađanjem
HRP20130071T1 (hr) Poboljšani testosteron u gelu i naäśin primjene
US6274566B1 (en) Methods for treating mammals with modified alginates and pectins
HRP20200971T1 (hr) Modulacija djelovanja epidermalnog faktora rasta koji veže heparin u svrhu zacijeljivanja membrane bubnjića
JP2006517928A (ja) 高用量のコンドロイチン硫酸を用いた膀胱炎の処置
HRP20201683T1 (hr) Imunogeni pripravak namijenjen upotrebi u terapiji
MX2024010596A (es) Composiciones que comprenden 5-metoxi-2-aminoindano (meai) y n-aciletanolaminas y usos de las mismas
HRP20192246T1 (hr) Marker za poremećaje kisele sfingomijelinaze i njegova uporaba
HRP20230823T1 (hr) Derivati deoksi-citidina za uporabu u terapijama raka
ES2633778T3 (es) Método de tratamiento o profilaxis de infecciones del ojo